Cepheid Gets FDA Clearance For Blood Clot Test
Stock quotes in this article:
CPHD
NEW YORK (AP) — Cepheid said Thursday it received Food and Drug Administration clearance for its Xpert test aimed at determining a person's genetic risk of developing blood clots.
The Xpert HemosIL FII & FV test is a 30-minute genetic test that analyzes genetic factors associated with thrombosis, or blood clots. Shares of Cepheid rose 68 cents, or 5.1 percent, to $14.12 in after-hours trading, after falling 80 cents, or 5.6 percent, to close at $13.44 during the regular trading session.- Loading Comments...
- Loading Comments...
Recent Comments
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,388.90 | 1,105.98 | 2,194.35 | 34.83 |
Oil *
77.03
|
|
UP
22.75
|
UP
6.06
|
UP
21.21
|
UP
1.03
|
10 Yr
3.48%
SPDR Gold
113.75
|
|
+0.22%
|
+0.55%
|
+0.98%
|
+3.05%
|
Data delayed 20 minutes |
